United States · Series A startup

Who invested in Ascent Therapeutics

One round we have observed, with the 4 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

HealthcareBiotech

Funding summaryUpdated 26 Oct 2026

$19Mraised across 1 round since 2007, from 1 source

Latest round
Series A, $19MNov 2007
Investors
4
See who backed them

The rounds

  1. Nov 2007

Founders and team

From the SEC filings it signed: 3 on the team.

  • Frederick JonesExecutive Officer, Directori
  • Stephen HuntExecutive Officeri
  • Thomas McMurryExecutive Officeri

On the board, as filediAthan KuliopulosChristopher K. MirabelliJens EcksteinLauren SilvermanMichael Webb

Everyone who backed them

Novartis Venture FundCorporate VC1round
TVM CapitalPrivate equity1round
HealthCare VenturesGrowth equity1round
Novartis BioventuresGrowth equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Ascent Therapeutics

Who invested in Ascent Therapeutics?

Ascent Therapeutics's investors include Novartis Venture Fund, TVM Capital, HealthCare Ventures and Novartis Bioventures.

How much has Ascent Therapeutics raised?

Ascent Therapeutics has raised $19M across 1 round since 2007.

When did Ascent Therapeutics last raise?

Ascent Therapeutics's most recent round was a Series A of $19M in Nov 2007.

What was Ascent Therapeutics's biggest round?

Its most recent round, $19M in Nov 2007, is also its largest on record.

Who backed Ascent Therapeutics first?

Ascent Therapeutics's first round on record, in Nov 2007, was backed by Novartis Venture Fund, TVM Capital and HealthCare Ventures and 1 others.

What stage is Ascent Therapeutics at?

Ascent Therapeutics's latest named round is a Series A, in Nov 2007.

Where is Ascent Therapeutics based?

Ascent Therapeutics is based in the United States.

Companies like Ascent Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.